Literature DB >> 11927013

Evaluation of an indicator for lymph node metastasis of esophageal squamous cell carcinoma invading the submucosal layer.

Yasuaki Nakajima1, Kagami Nagai, Satoshi Miyake, Kenichi Ohashi, Tatsuyuki Kawano, Takehisa Iwai.   

Abstract

Lymph node metastasis is a major prognostic factor for esophageal squamous cell carcinoma (ESCC). In recent years, endoscopic mucosal resection (EMR) has been developed with excellent results for the treatment of the superficial ESCC. To make the EMR treatment successful, it is important to establish a good indicator to identify ESCC patients at a high risk of lymph node metastasis. In this study, we examined clinicopathological and immunohistochemical factors to investigate the factors involved in lymph node metastasis of ESCC invading to the submucosal layer (sm-ESCC). Surgical specimens from 84 sm-ESCC patients were examined. Among 84 sm-ESCC patients, 33 (39.3%) had lymph node metastases. Clinicopathologically, tumor depth, lymphatic invasion and blood vessel invasion showed significant correlations with lymph node metastasis by univariate analysis. Tumor depth and lymphatic invasion showed significant correlations by multivariate analysis of these factors. Immunohistochemically, P53 accumulation was observed in 45 cases (53.6%), cyclin D1 overexpression in 25 (29.8%), and pRB in 65 (77.4%). P53 accumulation, cyclin D1 overexpression and MIB-1 Labeling Index were significantly associated with lymph node metastasis by univariate analysis, and P53 accumulation showed a significant correlation with lymph node metastasis by multivariate analysis. Among tumor depth, lymphatic invasion and P53 accumulation, tumor depth and lymphatic invasion were significantly correlated with lymph node metastasis (P = 0.0023 and P = 0.0092, respectively) by multivariate analysis. These data suggest that tumor depth and lymphatic invasion can be considered as good indicators for lymph node metastasis among patients with sm-ESCC. In addition, P53 accumulation could be helpful to identify the patients who need additional treatment after EMR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927013      PMCID: PMC5926972          DOI: 10.1111/j.1349-7006.2002.tb02173.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  41 in total

1.  P53 in tumour pathology: can we trust immunocytochemistry?

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1992-04       Impact factor: 7.996

2.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

3.  Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins.

Authors:  C C Kao; P R Yew; A J Berk
Journal:  Virology       Date:  1990-12       Impact factor: 3.616

4.  p53 protein expression in resected invasive esophageal cancer.

Authors:  L Chyczewski; M Kozłowski; J Nikliński; J Szyszko; J Laudański; W Niklińska
Journal:  Neoplasma       Date:  1999       Impact factor: 2.575

5.  Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer.

Authors:  E P Xing; G Y Yang; L D Wang; S T Shi; C S Yang
Journal:  Clin Cancer Res       Date:  1999-05       Impact factor: 12.531

6.  Endoscopic mucosal resection with a cap-fitted panendoscope for esophagus, stomach, and colon mucosal lesions.

Authors:  H Inoue; K Takeshita; H Hori; Y Muraoka; H Yoneshima; M Endo
Journal:  Gastrointest Endosc       Date:  1993 Jan-Feb       Impact factor: 9.427

7.  Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor).

Authors:  S Inada; T Koto; K Futami; S Arima; A Iwashita
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

8.  Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection.

Authors:  H A Lambkin; C M Mothersill; P Kelehan
Journal:  J Pathol       Date:  1994-01       Impact factor: 7.996

9.  Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus.

Authors:  H Takeuchi; S Ozawa; N Ando; C H Shih; K Koyanagi; M Ueda; M Kitajima
Journal:  Clin Cancer Res       Date:  1997-12       Impact factor: 12.531

Review 10.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

View more
  10 in total

Review 1.  Endoscopic resection of early oesophageal cancer.

Authors:  Oliver Pech; Andrea May; Thomas Rabenstein; Christian Ell
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

2.  Parameters predicting lymph node metastasis in patients with superficial esophageal squamous cell carcinoma.

Authors:  Liyan Xue; Liqun Ren; Shuangmei Zou; Ling Shan; Xiuyun Liu; Yongqiang Xie; Yueming Zhang; Jun Lu; Dongmei Lin; Sanford M Dawsey; Guiqi Wang; Ning Lu
Journal:  Mod Pathol       Date:  2012-05-25       Impact factor: 7.842

3.  Evaluating the Correlation Between the Survival Rate of Patients with Esophageal Squamous Cell Carcinoma and Expression of p53 and Cyclin D1 Biomarkers Along with Other Prognostic Factors.

Authors:  Nazanin Saemi; Jalaleddin Khoshnevis; Mohammad Esmaeil Akbari; Alipasha Meysamie; Alireza Korourian; Barmak Gholizadeh; Leila Larijani; Afshin Moradi; Masoud Baikpour; Maryam Baikpour; Hanieh Zham
Journal:  J Gastrointest Cancer       Date:  2018-03

4.  Mast cell density and the context of clinicopathological parameters and expression of p185, estrogen receptor, and proliferating cell nuclear antigen in gastric carcinoma.

Authors:  Ying-An Jiang; You-Yuan Zhang; He-Sheng Luo; Shou-Fu Xing
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

5.  Outcomes of patients receiving additional esophagectomy after endoscopic resection for clinically mucosal, but pathologically submucosal, squamous cell carcinoma of the esophagus.

Authors:  Satoru Motoyama; Mario Jin; Tamotsu Matsuhashi; Hiroshi Nanjo; Koichi Ishiyama; Yusuke Sato; Kei Yoshino; Tomohiko Sasaki; Akiyuki Wakita; Hajime Saito; Yoshihiro Minamiya; Hirohide Ohnishi; Jun-Ichi Ogawa
Journal:  Surg Today       Date:  2012-08-17       Impact factor: 2.549

Review 6.  Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review.

Authors:  George Sgourakis; Ines Gockel; Hauke Lang
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

7.  Esophagectomy for superficial esophageal cancer after non-curative endoscopic resection.

Authors:  Hiroshi Saeki; Masayuki Watanabe; Shinji Mine; Hironobu Shigaki; Shuichiro Oya; Akiyoshi Ishiyama; Tomohiro Tsuchida; Junko Fujisaki; Hideo Baba; Yoshihiko Maehara; Takeshi Sano
Journal:  J Gastroenterol       Date:  2014-08-02       Impact factor: 7.527

8.  A comprehensive methylation signature identifies lymph node metastasis in esophageal squamous cell carcinoma.

Authors:  Roshni Roy; Raju Kandimalla; Fuminori Sonohara; Masahiko Koike; Yasuhiro Kodera; Naoki Takahashi; Yasuhide Yamada; Ajay Goel
Journal:  Int J Cancer       Date:  2018-10-16       Impact factor: 7.396

9.  Association of the primary tumor's SUVmax with survival after surgery for clinical stage IA esophageal cancer: a single-center retrospective study.

Authors:  Yutaka Miyawaki; Hiroshi Sato; Naoto Fujiwara; Shuichiro Oya; Hirofumi Sugita; Yasumitsu Hirano; Tomohiko Yamane; Shinichi Sakuramoto; Kojun Okamoto; Shigeki Yamaguchi; Isamu Koyama
Journal:  Int J Clin Oncol       Date:  2019-12-23       Impact factor: 3.402

10.  Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma in Taiwan.

Authors:  Ming-Hung Hsu; Wen-Lun Wang; Tzu-Haw Chen; Chi-Ming Tai; Hsiu-Po Wang; Ching-Tai Lee
Journal:  BMC Gastroenterol       Date:  2021-08-03       Impact factor: 3.067

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.